CONSULTANT HAEMATOLOGIST
A/Prof Ashish Bajel
MBBS FRACP FRCPA
A/Prof Ashish Bajel is a Consultant Haematologist and Bone Marrow Transplant Physician at Peter MaCallum Cancer Centre and The Royal Melbourne Hospital. He also serves as the Co-Lead of Acute Leukemia and Myelodysplastic Syndrome at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital.
A/Prof Bajel has a strong commitment to clinical research and is the Principal or Associate Investigator on numerous early and late-phase clinical trials in leukemia, myeloproliferative neoplasms (MPNs), and cellular therapies. His primary interest lies in exploring novel drug treatments and cell-based therapies for haematological malignancies.
His research has been widely presented at national and international conferences and published in high-impact, peer-reviewed medical journals. Passionate about improving patient care and healthcare delivery, A/Prof Bajel contributes actively to national and international boards and working groups. His leadership has helped shape clinical guidelines and position statements for the management of various blood disorders.
He is currently on the Board of Directors of the Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) and plays an advisory role on the steering committees of several data registries.
A/Prof Bajel consults at the private suites at The Royal Melbourne Hospital and in Essendon.
Practice Interests
A/Prof Bajel brings extensive expertise in both benign and malignant haematological conditions. His areas of special interest include Leukemia, Lymphoma, Myeloma, Myeloproliferative disorders, Platelet and clotting disorders.
Dedicated to delivering patient-centred care, A/Prof Bajel strives to achieve the best possible outcomes for each of his patients through evidence-based, compassionate treatment.
Practice Locations
Dr Ashish Bajel consults privately through private suites at The Royal Melbourne hospital and in Essendon.
Being part of the larger Royal Melbourne Hospital and Peter MacCallum Cancer Centre Network enables patients to access the latest in clinical trials or treatments, and investigations as required.
Suite 11, Level 3
Private Medical Centre
The Royal Melbourne Hospital
Royal Parade
Parkville VIC 3050
Tel: 03 9968 0011 | Fax: 03 9969 0011
SaiMed Specialist Centre
161 Keilor Rd
Essendon VIC 3040
Tel: 03 9379 4114 | 03 9379 4545
Fax: 03 9379 4115
Hospital Accreditation
Clinical Interests Include:
Updated: September 2025
Languages Spoken (Other than English)
Hindi, Marathi
Extended Profile
Dr Ashish Bajel
– Key Research, Journal & Book Publications, Presentations &/or Awards
Key Research Publications
- Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W.Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021
- Thijssen R, Diepstraten ST, Moujalled D, Chew E, Flensburg C, Shi MX, Dengler MA, Litalien V, MacRaild S, Chen M, Anstee NS, Reljić B, Gabriel SS, Djajawi TM, Riffkin CD, Aubrey BJ, Chang C, Tai L, Xu Z, Morley T, Pomilio G, Bruedigam C, Kallies A, Stroud DA, Bajel A, Kluck RM, Lane SW, Schoumacher M, Banquet S, Majewski IJ, Strasser A, Roberts AW, Huang DCS, Brown FC, Kelly GL, Wei AH. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood. 2021 May 20;137(20):2721-2735.
- Fiorenza S, Routledge D, Collins J, Shipton M, Harrison S, Bajel A, Cavet J, Tholouli E, Gauthier J, Ritchie D. Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma. Bone Marrow Transplant. 2020 Jun;55(6):1172-1174.
- Sanders MA, Chew E, Flensburg C, Zeilemaker A, Miller SE, Al Hinai AS, Bajel A, Luiken B, Rijken M, Mclennan T, Hoogenboezem RM, Kavelaars FG, Fröhling S, Blewitt ME, Bindels EM, Alexander WS, Löwenberg B, Roberts AW, Valk PJM, Majewski IJ. MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. Blood. 2018 Oct 4;132(14):1526-1534.
- Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2018 Jan 25;378(4):331-344.
- Verstovsek S, Courby S, Griesshammer M, Mesa RA, Brachmann CB, Kawashima J, Maltzman JD, Shao L, Xin Y, Huang D, Bajel A. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leuk Res. 2017 Sep; 60:11-17.
- Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, Litzow MR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W.Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2017 May;23(5):767-775.
- Gregory G, Arumugaswamy A, Leung T, Chan KL, Abikhair M, Tam C, Bajel A, Cher L, Grigg A, Ritchie D, Opat S.Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.Neuro Oncol. 2013 Aug;15(8):1068-73.
- Iron homeostasis: new players, newer insights. Edison ES, Bajel A, Chandy M. Eur J Haematol. 2008 Dec;81(6):411-24.
- Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M.Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006 Apr 1;107(7):2627-32.
